STABLE AND SOLUBLE FORMULATIONS OF RECEPTOR TYROSINE KINASE INHIBITORS, AND METHODS OF PREPARATION THEREOF

摘要

The present disclosure relates to stable formulations of receptor tyrosine kinase inhibitors (TKI), e.g., pazopanib; methods of preparation thereof; and use of the disclosed formulations in sustained delivery of the active agent to a target site. The disclosure further relates to methods of converting one polymorphic Form of a TKI to another polymorphic Form and/or an amorphous form.

主权项

1. A stable pharmaceutical formulation comprising about 30 mg/mL to about 40 mg/mL of a pharmaceutically acceptable monovalent or divalent salt of a therapeutic agent having low aqueous solubility, and a complexing agent; wherein the salt of the therapeutic agent is in solution in the formulation.